3SBIO Reports Fiscal Year Profit Attributable to Owners Soars 305.8% to RMB 8.482 Billion

Stock News03-30

3SBIO (01530) announced its full-year results for the period ending December 31, 2025. The Group's revenue increased by 94.3% to RMB 17.696 billion. Gross profit rose by 108.8% to RMB 16.347 billion, with a gross profit margin of 92.4%. Profit attributable to owners of the parent company surged by 305.8% to RMB 8.482 billion. A final dividend of 25 HK cents per share was declared.

3SBIO is a leading biotechnology company in Mainland China. As a pioneer in China's biotech sector, the Group possesses extensive experience in the research, development, production, and marketing of biopharmaceutical products. Its core commercial products include several biologics, such as TPIAO, the recombinant human erythropoietin (rhEPO) products YIBAIO and CIPHER, YISAIPU and CYRAMZA, as well as the minoxidil drug series from its small molecule product pipeline, MINIDI.

TPIAO is currently the world's only commercialized recombinant human thrombopoietin (rhTPO) product. According to IQVIA, in 2025, TPIAO held a 60.4% share of the thrombocytopenia treatment market in Mainland China by sales value. With its two rhEPO products, the Group has been the leader in the Mainland China rhEPO market for over two decades, collectively capturing 39.6% of the total market share in 2025. YISAIPU was the first tumor necrosis factor (TNF) α inhibitor product launched in the Mainland China market. MINIDI also holds a dominant position in the hair loss treatment drug market in Mainland China. The Group is further expanding its therapeutic areas by increasing its product portfolio through internal R&D efforts and various external strategic collaborations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1194363500?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 22:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194363500","market":"nz","top_or_hot":-1,"title":"3SBIO Reports Fiscal Year Profit Attributable to Owners Soars 305.8% to RMB 8.482 Billion","media":"Stock News","content":"<p>3SBIO (01530) announced its full-year results for the period ending December 31, 2025. The Group's revenue increased by 94.3% to RMB 17.696 billion. Gross profit rose by 108.8% to RMB 16.347 billion, with a gross profit margin of 92.4%. Profit attributable to owners of the parent company surged by 305.8% to RMB 8.482 billion. A final dividend of 25 HK cents per share was declared.</p>\n<p>3SBIO is a leading biotechnology company in Mainland China. As a pioneer in China's biotech sector, the Group possesses extensive experience in the research, development, production, and marketing of biopharmaceutical products. Its core commercial products include several biologics, such as TPIAO, the recombinant human erythropoietin (rhEPO) products YIBAIO and CIPHER, YISAIPU and CYRAMZA, as well as the minoxidil drug series from its small molecule product pipeline, MINIDI.</p>\n<p>TPIAO is currently the world's only commercialized recombinant human thrombopoietin (rhTPO) product. According to IQVIA, in 2025, TPIAO held a 60.4% share of the thrombocytopenia treatment market in Mainland China by sales value. With its two rhEPO products, the Group has been the leader in the Mainland China rhEPO market for over two decades, collectively capturing 39.6% of the total market share in 2025. YISAIPU was the first tumor necrosis factor (TNF) α inhibitor product launched in the Mainland China market. MINIDI also holds a dominant position in the hair loss treatment drug market in Mainland China. The Group is further expanding its therapeutic areas by increasing its product portfolio through internal R&D efforts and various external strategic collaborations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3SBIO Reports Fiscal Year Profit Attributable to Owners Soars 305.8% to RMB 8.482 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3SBIO Reports Fiscal Year Profit Attributable to Owners Soars 305.8% to RMB 8.482 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-30 22:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>3SBIO (01530) announced its full-year results for the period ending December 31, 2025. The Group's revenue increased by 94.3% to RMB 17.696 billion. Gross profit rose by 108.8% to RMB 16.347 billion, with a gross profit margin of 92.4%. Profit attributable to owners of the parent company surged by 305.8% to RMB 8.482 billion. A final dividend of 25 HK cents per share was declared.</p>\n<p>3SBIO is a leading biotechnology company in Mainland China. As a pioneer in China's biotech sector, the Group possesses extensive experience in the research, development, production, and marketing of biopharmaceutical products. Its core commercial products include several biologics, such as TPIAO, the recombinant human erythropoietin (rhEPO) products YIBAIO and CIPHER, YISAIPU and CYRAMZA, as well as the minoxidil drug series from its small molecule product pipeline, MINIDI.</p>\n<p>TPIAO is currently the world's only commercialized recombinant human thrombopoietin (rhTPO) product. According to IQVIA, in 2025, TPIAO held a 60.4% share of the thrombocytopenia treatment market in Mainland China by sales value. With its two rhEPO products, the Group has been the leader in the Mainland China rhEPO market for over two decades, collectively capturing 39.6% of the total market share in 2025. YISAIPU was the first tumor necrosis factor (TNF) α inhibitor product launched in the Mainland China market. MINIDI also holds a dominant position in the hair loss treatment drug market in Mainland China. The Group is further expanding its therapeutic areas by increasing its product portfolio through internal R&D efforts and various external strategic collaborations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"","article_id":"1194363500","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194363500","pubTimestamp":1774881158,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"3SBIO (01530) announced its full-year results for the period ending December 31, 2025. The Group's revenue increased by 94.3% to RMB 17.696 billion. Gross profit rose by 108.8% to RMB 16.347 billion,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","BK1593":"医美概念股","BK1161":"生物科技","01530":"三生制药"},"translate_title":"三生制药公布财年拥有人应占利润飙升305.8%至人民币84.82亿元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1},"content_text":"3SBIO (01530) announced its full-year results for the period ending December 31, 2025. The Group's revenue increased by 94.3% to RMB 17.696 billion. Gross profit rose by 108.8% to RMB 16.347 billion, with a gross profit margin of 92.4%. Profit attributable to owners of the parent company surged by 305.8% to RMB 8.482 billion. A final dividend of 25 HK cents per share was declared.\n3SBIO is a leading biotechnology company in Mainland China. As a pioneer in China's biotech sector, the Group possesses extensive experience in the research, development, production, and marketing of biopharmaceutical products. Its core commercial products include several biologics, such as TPIAO, the recombinant human erythropoietin (rhEPO) products YIBAIO and CIPHER, YISAIPU and CYRAMZA, as well as the minoxidil drug series from its small molecule product pipeline, MINIDI.\nTPIAO is currently the world's only commercialized recombinant human thrombopoietin (rhTPO) product. According to IQVIA, in 2025, TPIAO held a 60.4% share of the thrombocytopenia treatment market in Mainland China by sales value. With its two rhEPO products, the Group has been the leader in the Mainland China rhEPO market for over two decades, collectively capturing 39.6% of the total market share in 2025. YISAIPU was the first tumor necrosis factor (TNF) α inhibitor product launched in the Mainland China market. MINIDI also holds a dominant position in the hair loss treatment drug market in Mainland China. The Group is further expanding its therapeutic areas by increasing its product portfolio through internal R&D efforts and various external strategic collaborations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1194363500","isCrawlerRequest":true}